Five questions for: Cara Therapeutics CEO Derek Chalmers
This article was originally published in Scrip
Cara Therapeutics is one of 19 biotechnology firms to launch an initial public offering so far in 2014, so with $55.9m in IPO proceeds in the bank, president and CEO Derek Chalmers can focus on his company's late-stage development of CR845 for post-operative pain.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.